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Abstract
Objective: To assess the efficacy and safety of preventing the acquisition of ventilatorassociated pneumonia with the use of probiotic supplementation, as compared to a placebo,
among hospitalized adult men and women receiving more than 24 hours of mechanical
ventilation. Design: Systematic Literature Review. Methods: Systematic searches were
conducted through PubMed and Scopus using the search terms “ventilator”, “probiotics”, and
“prevention”. Records were excluded from the analysis if they were published before 2015, full
text was not available, studies other than randomized control trial or cohort studies, and if the
study population was less than 18 years old. Results: Of the four studies, only one had
statistically significant findings. In the study, incidence of ventilator-associated pneumonia
(VAP) was reduced in the probiotic group, probability of remaining VAP-free was significantly
higher in the probiotic group, and mean time of onset of VAP after endotracheal intubation was
significantly longer in the probiotics group. Conclusion: Probiotics are generally safe to
administer and may aid in the immune response of the host; however more research and welldesigned studies are needed to definitively determine the effectiveness of probiotics in the
prevention of VAP in hospitalized mechanically ventilated patients.
Introduction
Ventilator-associated pneumonia (VAP) is one of the most commonly diagnosed
nosocomial bacterial infections in the intensive care unit (ICU), with reported incidences as high
as 78%.1 It is defined as a type of healthcare acquired pneumonia that develops after 48 hours of
endotracheal intubation.2 It is believed that endogenous flora in the oral cavity and upper airway
play a significant role in VAP development, with micro-aspiration around the endotracheal tube
cuff being the major route of transmission.3 VAP prolongs the duration of mechanical
ventilation, ICU, and hospital stays, with increased medical costs.1,4 In 2013, the estimated cost
of VAP, with risk of complications, was between $10,000 to $60,000 USD.5 Additionally,
morbidity and mortality increase with a crude rate of 24-75% with VAP patients.4 Various
pharmacologic and non-pharmacologic techniques are implemented in the ICU to reduce the
incidence of VAP. One pharmacologic method involves attenuation of burden of bacterial
colonization in the upper digestive tract by antibiotic use.1 However, with the increasing
incidence of antibacterial resistance in ICUs and the lack of new antibiotics, there is significant
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concern for development of antibiotic resistant pathogens in this critically ill population. Further
prevention strategies that do not involve parenteral antibiotic use should be investigated due to
the significant incidence, morbidity, and mortality of VAP.
Research is ongoing to identify the potential positive impacts of probiotics in medicine.
Probiotics have been projected to exert beneficial effects by enhancing gut barrier function,
inhibiting colonization of potentially pathogenic microorganisms, maintaining a normal intestinal
milieu, synthesizing antibacterial substances, and stimulating local immunity.1 Current species of
probiotics that are being researched include Lactobacillus, Bifidobacterium, Streptococcus, and
Saccharomyces, among others. In one study, Lactobacillus casei (Shirota strain) (LcS) showed
inhibitory activity against multi-drug resistant bacteria, including Acinetobacter baumannii,
Pseudomonas aeruginosa, extended spectrum beta-lactamase-producing Escherichia coli,
Klebsiella pneumoniae, and MRSA, resulting in eradication of such organisms at 24 hours in a
laboratory-controlled setting.6 This suggests potential for this strain and others to inhibit
common pathogens responsible for VAP, such as Pseudomonas aeruginosa, Staphylococcus
aureus, and other gram-negative bacilli.2
Probiotics have a high safety profile, have no obvious contraindication or adverse effects,
and are cost effective for patients at less than $2 per day, spurring significant research interest in
the medical field.1, 5, 7 Probiotics are also easily administered to patients by medical staff with an
estimated time of less than five minutes per day. Several studies have been conducted to show
probiotic effectiveness in decreasing the length of ICU stays and reducing VAP-related
mortality. This literature review will compare four studies since the last meta-analysis
publication to determine if probiotic supplementation prevents the acquisition of VAP and
decreasing associated rates of morbidity and mortality.
Methods
Searches were conducted on both PubMed and Scopus in September of 2018 using the
search terms “ventilator”, “probiotics”, and “prevention”. Duplicates between the two databases
were removed and then screened, excluding those before the last meta-analysis publication date
(2015) and if full text was not available. Full text articles were then reviewed for eligibility and
were removed if they were not randomized controlled trials or cohort studies, or if the study
population was less than 18 years of age. Four promising studies remained and were reviewed.
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The PRISMA for this literature review is demonstrated in Figure 1. Study 1 evaluated the
incidence of VAP after administration of probiotic Lactobacillus casei (Shirota strain) by oral
care once daily and enteral feeding once daily. Study 2 evaluated the incidence of VAP after
administration of combination probiotic containing Bacillus subtilis and Enterococcus faecilis by
enteral feeding once daily. Study 3 evaluated the incidence of VAP after administration of
combination probiotic containing Lactobacillus acidophilus (gasseri) and Lactobacillus
helveticus (bulgaricus) by tablet twice daily. Study 4 evaluated the incidence of VAP after the
administration of combination probiotic containing Lactobacillus (casei, acidophilus,
rhamnosus, bulgaricus), Bifidobacterium (breve, longum) and Streptococcus thermophiles
species by two capsules, every 12 hours, administered via enteral feeding.

Figure 1. PRISMA depicting the algorithm for identifying appropriate studies that utilize probiotics in ventilatorassociated pneumonia prevention to be reviewed in this literature review.
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Results
Study 1
Randomized Controlled Study of Probiotics Containing Lactobacillus casei (Shirota strain) for
Prevention of Ventilator-Associated Pneumonia. Rongrungruang et al., 2015.
Objective
To evaluate the efficacy of probiotics, Lactobacillus casei (Shirota strain), in reducing the
incidence of VAP in medical patients who received mechanical ventilation at Siriraj Hospital in
Thailand.
Design
This study was a prospective, randomized, open-label controlled trial at a 2,300-bed
tertiary care university in Bangkok from May 2011 to August 2013. A combined 150 patients
were enrolled, with 75 in the probiotics group and 75 in the control. Most study patients were
elderly females with comorbidities and severe health problems leading to mechanical ventilation.
Baseline characteristics of the patients in both groups were not significantly different. Study
patients were included if they were at least 18 years of age and were expected receive at least 72
hours of mechanical ventilation during their hospitalization. Pediatric patients and those had
current VAP upon enrollment were excluded.
The study group received 80 ml of commercially-available fermented dairy product
(Yakult ®) containing 8x109 colony-forming units (cfu) of LcS for oral care once daily following
standard oral care with chlorhexidine. An additional 80 ml was given via enteral feeding once
daily for 28 days, or when the patient’s endotracheal tube was removed. Probiotics
administration was discontinued when diarrhea related to probiotics occurred. The patients in the
control group did not receive any additional products.
All patients received standard VAP preventive bundle techniques as per the Siriraj
Hospital protocol. All patients received oral care four times daily with 2% chlorhexidine oral
solution.
Patients were observed for the primary outcomes of VAP incidence, and VAP episodes
per 1,000 ventilator days. A diagnosis of VAP was made if the patient had a new, persistent, or
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progressive infiltrate visible on chest radiograph in combination with at least three of the
following criteria: (1) Body temperature >38°C or <35.5°C; (2) Leukocytosis (>10,000
leukocytes/mm3 or leukopenia (<3,000 leukocytes/mm3); (3) Purulent tracheal aspirate; (4) A
semi-quantitative culture of tracheal aspirate samples that was positive for pathogenic bacteria.
Results
There were no statistically significant differences in primary or secondary outcomes
reviewed in this study between the study and control groups (p < 0.05). Acinetobacter baumannii
was the most common cause of VAP in both groups.
Critique
The study was an open-label design, with the control patients, care team, and patient
knowing which patient received which care which allows potential for bias. The sample size of
150 participants was originally hypothesized to be appropriate to show statistical significance
between the study and control groups with 5% type I error and 80% power, though this was
found to be too small. The population was also predominantly females which does not
demonstrate equal efficacy between sexes.
The dose of probiotics by enteral or oral administration may have been too low or
administered too infrequently for adequate prophylaxis from VAP. The study did not identify the
specific VAP-prevention techniques implemented by Siriraj Hospital other than chlorhexidine
four times daily. The authors identify that preceding LcS oral care with chlorhexidine may have
caused death of the LcS probiotic and impact its efficacy in preventing VAP.
Study 2
Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients:
a randomized controlled multicenter trial. Zeng et al., 2016.
Objective
To assess the effectiveness of probiotics Bacillus subtilis and Enterococcus faecalis in the
prevention of VAP when administered by nasogastric (NG) tube.
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Design
This study was a prospective, open-label, randomized controlled multicenter study
involving 11 participating ICUs in nine Chinese teaching hospitals between May 2010 and April
2015. Patients included were adults at least 18 years of age but less than 80 years of age with an
expected need for mechanical ventilation for at least 48 hours. Exclusion criteria were age less
than 18 or greater than 80 years of age, severe multiple organ failure (with an Acute Physiology
and Chronic Health Evaluation (APACHE) II score of ≥25), mechanical ventilation longer than
72 hours prior to enrollment, failure of enteral feeding, administration of immunosuppressive
diseases (e.g. malignant tumor, acquired immune deficiency syndrome, human
immunodeficiency virus carriers), and pregnancy or lactation. A total of 234 patients was
estimated to have statistical power of 80%, with patients randomized equally into study and
control groups.
The study group was administered probiotics three times daily in addition to standard
preventive strategies for VAP. Each capsule contained 4.5 x109 cfu/0.25 g Bacillus subtilis and
0.5 x109 cfu/0.25 g Enterococcus faecalis. The capsule was opened and diluted in 50-80 ml of
sterile water and administered as a bolus through NG tube. Researchers recorded compliance to
the regimen and considered over 80% adherence of study medication as compliant. The control
group did not receive placebo treatment.
Both groups received standard preventive strategies for VAP, including daily screening
for weaning from mechanical ventilation potential as soon as possible, hand hygiene, aspiration
precautions, and prevention of contamination. All patients were placed in a semi-recumbent
position in absence of contraindication. Endotracheal pressure cuff was continuously controlled
at around 25 cm H2O to prevent regurgitation and aspiration. An endotracheal tube which
enabled subglottic secretion aspiration was the first choice and preferred over normal tracheal
tube. Until enteral feeding was established, all patients admitted to the ICU received IV proton
pump inhibitor (PPI) as stress ulcer prophylaxis. Endotracheal suctioning was performed by the
nursing staff if necessary. Tracheotomy was performed when ventilation was anticipated to be
necessary for greater than three weeks. Normal oropharyngeal care measures included rinsing the
mouth with water and, if possible, brushing the teeth once daily.
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A clinical diagnosis of VAP was based on the presence of new, persistent or progressive
infiltrate on chest radiographs that persisted for at least 48 hours (as interpreted by radiologists
blinded to the patients’ treatment assignments) combined with at least two of the following
criteria: (1) temperature >38.0°C or <35.5°C; (2) leukocytosis >12,000/mm3 or leukopenia
<3000/mm3 and/or left shift; (3) purulent tracheal aspirates. All clinical diagnoses of VAP were
evaluated and agreed upon by two of the authors.
Primary endpoints were the proportions of eradication of colonization and acquired
colonization with potentially pathogenic microorganisms in the oropharynx and stomach, and the
incidence of microbiologically-confirmed VAP in patients intubated for at least 48 hours.
Results
Microbiologically-confirmed VAP was significantly reduced in the probiotics (36.4%)
compared to the control (50.4%) (p = 0.031). The probability of remaining VAP-free was
significantly higher in the probiotics group as well by log-rank analysis (p = 0.004) (Figure 2).
Finally, the mean time of onset of VAP after endotracheal tube intubation was significantly
longer in the probiotics group compared to control (10.4 days compared to 7.5 days,
respectively; p = 0.022). All other primary and secondary endpoints did not demonstrate
significant difference.
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Figure 2. The probability of remaining ventilator-associated pneumonia-free (VAP-free) during the study period in
the probiotics and control groups.

Of additional note, there were no statistically significant differences in the pathogens
isolated from patients diagnosed with VAP in either the study or control group. The most
common gram-negative pathogens isolated were Pseudomonas aeruginosa and Acinetobacter
baumannii. The most common gram-positive pathogen isolated was Staphylococcus aureus.
Critique
This was an open-label study which limited blinding. While radiologists interpreting
chest radiographs were blinded, the lack of the control group receiving treatment allowed the
care teams and patients to be aware of the treatment regimens being administered. This openlabel study was notably strict on VAP diagnosis in requiring two of the study’s authors to agree
upon the clinical diagnosis to be deemed significant. The significant results listed was
microbiologically-confirmed VAP though stated clinically diagnosed VAP was not significant.
Microbiologically-confirmed VAP was achieved by identifying moderate or heavy growth on
cultures of endotracheal aspirate
There was no statistical significance between the pathogens or their respective prevalence
between the study and control groups. P. aeurginosa was isolated in 13/56 (23.2%) patients with
VAP in the study group and 19/67 (28.4%) of the control. A. baumannii was isolated in 10/56
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(17.9%) and 14/67 (20.9%) in study and control groups, respectively. S. aureus was isolated in
12/56 (21.4%) and 16/67 (23.9%) in study and control groups, respectively. Without significant
pathogenic difference between the study and control, despite statistical significance in incidence
of microbiologically-confirmed VAP, questions are raised as to the mechanism by which
probiotics prevent VAP, or the significance of the findings within this study.
Study 3
Effect of Probiotics on the Incidence of Healthcare-Associated Infections in Mechanically
Ventilated Neurocritical Care Patients. Kenna et al., 2016.
Objective
The objective of this study was to examine the safety and effectiveness of probiotic
administration in the reduction of HAIs, including VAP, among medically ventilated
neurocritical care patients.
Design
This study design was assembled into two retrospective cohorts and took place in a 12bed NCCU tertiary care academic medical center. A total of 167 patients were included in the
study. 80 of those patients were assigned to the pre-intervention cohort that took place from July
1, 2011 to December 31, 2011. This cohort included the supplementation of probiotics via one
packet (100,000,000 cfu/packet) or four tablets (1,000,000 cfu/tablet) of Lactobacillus
acidophilus (gasseri) and Lactobacillus helveticus (bulgaricus) administered twice daily by
nursing staff. The additional 87 patients were assigned to the post-intervention cohort from July
1, 2012 to December 31, 2012. Probiotic supplementation was not utilized in the postintervention cohort.
Patient criteria included mechanically ventilated individuals who were admitted to the
tertiary care academic medical center. Exclusion criteria applied to patients who were
immunocompromised or had a lactose allergy. Researchers defined immunocompromised
patients as those with a history of human immunodeficiency virus, current chemotherapy,
transplantation, or based on neurocritical care attending’s discretion. Furthermore, vulnerable
populations were excluded from the study to improve probiotic compliance after a phase-in
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period in June 2012. These populations included children under 18 years old, pregnant women,
and prisoners.
Ultimately, the study measured the incidence of HAIs (primary outcome) and the number
of antibiotic days, ventilator days, length of ICU stay, in-hospital mortality, and discharge status
(secondary outcomes). HAIs are defined as central line-associated bloodstream infection,
catheter-associated urinary tract infection, ventilator-associated pneumonia, catheter-associated
ventriculitis, and Clostridium difficile infection. Categorical variables were analyzed using
Fisher’s exact test. Non-normally distributed continuous variables were analyzed using the
Wilcoxon rank sum test. Statistical analysis was based on intention to treat and conducted using
Stata SE versions 10 and 13. Statistical significance was defined as p < 0.05.
Results
Of the 167 patients who participated in the study, baseline characteristics were overall
similar between the pre- and post-intervention retrospective cohorts. There were no significant
clinical differences between the study population and the control population
Median age (59 years vs 62 years) and percent male (45% vs 48%) were similar between
pre- and post- cohorts. Majority of patients were admitted for traumatic brain injury, intracranial
hemorrhage, and subarachnoid hemorrhage (p = 0.17). Use of enteral nutrition (UN), steroids
and antibiotics were similar between groups, however patients in the probiotic group received
more antibiotics. No patients in the pre-intervention group received probiotics. Eighty-five
(98%) patients in the pre-intervention group received probiotics for an average of 10 days. The
two patients who did not receive probiotics had a change in care to advanced comfort measures.
When comparing patient outcomes, there were 14 (18%) HAIs in the pre-intervention
group and 8 (9%) HAIs in the post-intervention group (p = 0.17). Ventilator days, ICU days,
lengths of stay, in-hospital mortality, and discharge disposition were similar between cohorts.
There were no adverse events from use of Lactobacillus supplementation.
The authors of the study were able to conclude probiotics are safe to administer in
neurocritical patients, however there are no significant decreases in HAIs or secondary outcomes
associated with probiotics.
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Critique
This study was able to demonstrate probiotics are safe in neuro-critically ill patients. In
addition to safety, compliance with probiotic administration was ensured with 98% of patients
receiving intervention. Adherence to protocol was achieved through daily rounds by the
neurocritical care team.
There are several limitations to this study. The location of the tertiary care academic
medical center was not specified in the article. This study was broadly focused on HAIs, with
VAP incidence being only one of the outcomes reviewed. This could be a limitation in our
systemic analysis by overgeneralizing the study outcomes to HAIs. Due to the retrospective
nature, the authors were unable to account for bias from unmeasured changes in care over the
study time period. However, selection bias was minimized by including patients from a preselected time frame with complete data. The smaller sample size of 167 patients restricted the
ability to show real significance. This may be a reason for the lack of association between the
reduction of VAP in neurocritical patients with the use of probiotics.
The authors described the study as “unpowered” without further description. In order to
detect an 8% difference with 80% power, there needed to be 530 patients in total, making 265
patients per treatment group. The study also included unmeasured or unknown variables that may
have influenced the overall outcome. It was not stated how probiotics were administered and the
type of enteral nutrition each patient received was not recorded, which may have had unknown
interactions with the probiotics. Additionally, the ideal dosing, duration, and type of probiotics
were unknown to the authors when creating the study and were chosen based off the availability
in the medical center.
Study 4
Effect of a Probiotic Preparation on Ventilator-Associated Pneumonia in Critically Ill Patients
Admitted to the Intensive Care Unit: A Prospective Double-Blind Randomized Controlled Trial.
Mahmoodpoor et al., 2018.
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Objective
The objective of this study was to examine the safety and effectiveness of probiotic
administration in decreasing the incidence of VAP in critically ill patients admitted to the
surgical ICU.
Design
This study was a randomized control trial approved by the ethics committee of Tabriz
University of Medical Sciences. It was coordinated in two university-affiliated hospitals in
northwest Iran from January 2015 to September 2016. Investigators consisted of primary care
physicians, nurses, and laboratory employees who were blinded to the study. A total of 120
critically ill patients in the surgical ICUs were enrolled in the study, who were then randomized
into two groups. One group received probiotics and the other received placebo during the whole
study period, excluded from the study or until death. Patients in the probiotic group received two
capsules, every 12 hours for 14 days, administered through enteral feeding. The method for
enteral feeding was performed via nasogastric tube with size 16F. Feedings were administered
seven times a day. The supplements contained 1x1010 cfu consisting of Lactobacillus (casei,
acidophilus, rhamnosus, bulgaricus) Bifidobacterium (breve, longum) and Streptococcus
thermophiles species. The placebo contained sterile maize starch, which looked identical to the
probiotics. Supplementation was given via feeding tube. If the patient could not tolerate enteral
nutrition, the patients were excluded from the study.
All patients received the same routine care involving standard precautions for VAP
prophylaxis, such as hand washing, suctioning, endotracheal tube with subglottic secretion
drainage, heat and moisture filtering, sedation, oral hygiene, changing ventilator circuit, and use
of antibiotics. Patient inclusion criteria for the study consisted of critically ill patients 18 years of
age or older who were admitted to the ICU and had been undergoing mechanical ventilation for a
minimum of 48 hours. Patient exclusion criteria included previous history of pneumonia,
pregnancy, immunosuppression, prosthetic cardiac valve or valvular graft, history of rheumatic
fever, recent gastroesophageal or intestinal injury, placement of tracheostomy, and patient
refusal. Furthermore, outcomes being measured were defined as primary or secondary. Primary
outcomes were VAP occurrence, and secondary outcomes were mortality, ICU length of stay,
duration of mechanical ventilation, and adverse events of probiotic use. Probiotic effectiveness
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was analyzed through gut microbial flora in gastric aspirates on the first, third, and seventh days
after clinical diagnosis of VAP. All patients with associated diarrhea were also evaluated for
Clostridium difficile.
Results
Of the 120 patients involved in the study, the baseline characteristics were very similar
between probiotic (n=48) and placebo (n=54) groups. The cerebrovascular accident group
comprised those with intracerebral hemorrhage, hypoxemic encephalopathy, ischemic stroke,
and brain tumor. The neurological event group covered patients with myasthenia gravis and
Guillain-Barré syndrome.
The two groups did not show significant difference between VAP risk factors. Smoking,
chronic obstructive pulmonary disease, chest trauma, alcohol consumption, and prolonged
duration of ICU stay were considered risk factors for VAP. There were no adverse effects from
Lactobacillus species, Bifidobacterium species and Streptococcus thermophiles probiotics. ICU
mortality and length of mechanical ventilation did not significantly differ between groups.
Patients receiving probiotics did show lower incidence of microbiologically-confirmed VAP and
the duration of ICU or hospital stay was lower. However, after applying the Kaplan-Meier
survival curve to compare time to the first episode of VAP, there was no statistical significance
between control and probiotic groups.
Critique
Strengths of the study include the double-blind design and the confirmation of VAP
based on microbiological criteria. Unintentional biases were also minimized by the rate of
compliance to VAP prevention bundles (85%).
Limitations of this study include the small sample size of 120 and the limited number of
hospitals enrolled. Most patients involved were surgical cases where the patients were
mechanically ventilated for a short duration of time making VAP occurrence rare. Lastly, the
ideal dosing, duration, and probiotic strains used were based on the availability in the two ICU
centers, not based on the ideal strand for VAP.
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Discussion
Ventilator-associated pneumonia in the United States is most commonly due to S. aureus
(MSSA, MRSA), P. aeruginosa, Klebsiella spp, Enterobacter spp, Acinetobacter baumannii, E.
coli, Stenotrophomonas maltophilia, and other microorganisms.8, 9 Clinical benefit of probiotic
use is still uncertain, with studies adjusting specific strains, combinations, or concentrations for a
variety of health conditions. Some probiotic strains utilized in this analysis show evidence of
protection versus the potentially pathogenic specimens that most commonly cause VAP. As
previously mentioned, Tiengrim and Thamlikitkul found significant protective potential against
many of the VAP-associated organisms by use of LcS.6 They proposed that LcS inhibits the
growth of the organisms by the products it creates by fermenting the milk, notably lactic acid.6
The study by Tiengrim and Thamlikitkul was of significant clinical interest and motivation
behind the pursuit of Study 1 by Rongrungruang et al. Study 1 was unique in its composition as
it provided a fermentable medium for LcS, with the idea that the fermentable product of lactic
acid may add a gastrointestinal protective agent. While Study 1 did not reach statistical
significance, the fermentable medium used brings a unique idea emphasizing the potential
complexity to the clinical utilization of probiotics.
Bacillus spp have been shown to produce antimicrobial substances, enhance epithelial gut
barrier functions, and stimulate cytokine and systemic immunoglobulin A (SIgA) release in
humans.10 SIgA is the predominant immunoglobulin class in human external secretions and is
essential in the maintenance of gut microbiota homeostasis and in the protection of
gastrointestinal and respiratory tract pathogens.10 In a randomized, double-blind, placebocontrolled study, B. Subtilis CU1 strain was found be an immune system stimulator in the elderly
during a common infectious disease period.10 The study found that B. subtilis CU1 significantly
increased the levels of SIgA detected by saliva and stool analysis.10 The authors note the
importance of this finding because production of SIgA at mucosal surfaces decreases with age
and can lead to an increased risk of infection.10
Study 2 by Zeng et al. reviewed a probiotic regimen of 90% B. subtilis combined with
10% E. Faecalis. The data from the study show a significant decrease in microbiologicallyconfirmed VAP incidence in the study group compared to the control. Though SIgA was not
measured as a primary or secondary outcome in the study, previous data supports the role of B.
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subtilis in increased SIgA which could explain the seemingly nonspecific reduction in incidence
of VAP. Recall that the organisms isolated did not statically differ between the study and control,
however, with the most predominant organisms being P. aeruginosa, A. baumannii, and S.
aureus. The patients in the study did not significantly vary in their reason for intubation or the
nature of their admission (medical, elective or emergent surgical), however it cannot be stated
that there is no significant difference in the stressors experienced by the patients stratified into
each group based on their medical condition. This is important to note because SIgA secretion
appears to be modulated by stress.10, 11 While Study 2 was open-label and did not blind its
patient, healthcare team, or researchers, the significance of the results may be clinically
important when considering sequelae of probiotic administration.
Enterococcus faecalis was paired with B. subtilis in Study 2. E. faecalis is a part of
normal gut flora, however it also is of concern for opportunistic pathogenicity.12 The reasoning
for the choice of probiotic strains by the authors in Study 2 is not explicitly stated. Additionally,
it is unclear if the authors recognize the potential pathogenicity of Enterococcus spp. The authors
identify that administration of a probiotic yogurt containing Lactobacillus rhamnosus GG was
associated with significant reduction in gastrointestinal carriage of vancomycin resistant
enterococci.1 Having a low supplemental dosage in the significantly higher presence of nonpathogenic B. subtilis may promote the maintenance of normal gut microbiome, though there is
concern for Enterococcus spp VAP.8, 9
There are multiple variables that were inconsistent across the studies. Briefly mentioned
was the concentration of probiotics used per administration, use of a medium within which the
probiotics were diluted (milk product, sterile water, tablet), route (oral cleanse, naso- or
orogastric tube), and frequency of administration. Each of these variables could be altered and
the incidence of VAP be observed since there is no accepted standard for any variable at this
time. Study 2 was the single study in this review to identify significant difference between VAP
incidence. The total probiotics administered amounted to 5.0x109 cfu administered by enteral
feeding once daily. Other studies reviewed all had higher concentrations of cfu administered,
were administered multiple times daily, and Study 1 had the added oral care administration of
their study strain of LcS. This variability with lack of significance suggests strains may be more
important compared to amount of cfu, frequency, or route of administration.
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The diagnostic requirements from each study varied (Table 1). Study 3 focused on all
HAIs with having incidence of VAP as one of the infections reviewed. Due to this, it cannot be
compared to the requirements of other studies. Studies 1, 2, and 4 have similar criteria required,
with some slight differences in temperature and leukocyte count or bandemia requirements. As
previously mentioned, Study 2 split the primary outcomes into clinically diagnosed VAP (Table
1) and microbiologically-diagnosed VAP (described in the critique for Study 2). The statistically
significant differences of these two outcomes varied, with only microbiologically-diagnosed
VAP being significant. By separating clinical from microbiological, there may be added benefit
in requiring microbiology to confirm VAP diagnosis. However, this could also show that there
was added scrutiny in Study 2, an open-label randomized controlled trial. Two of the authors had
to agree upon the clinical diagnosis of VAP which may be added scrutiny that could bias the
results (Table 1).
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Table 1. The ventilator-associated pneumonia diagnostic requirements respective to each study reviewed.
VAP = ventilator-associated pneumonia; CXR = chest X-ray radiograph; cfu = colony-forming units

Diagnostic
criteria

Study 1
Presence of new,
persistent, or
progressive infiltrate
on chest radiograph
in combination with
at least 3 of the
following criteria:

Study 2*
Presence of new,
persistent, or
progressive infiltrate
on chest
radiographs that
persisted for ≥48
hours, combined
with 2 of the
following criteria:

Study 3
Not specified in this
study

Study 4
Presence of new or
persistent infiltration
on CXR with 2 of the
following criteria:

1) Temperature
>38.0°C or <35.5°C

1) Temperature of
>38.0°C or <35.5°C

1) Temperature
>38.0°C or <36.0°C

2) Leukocytosis
>10,000/mm3 or
leukopenia
<3,000/mm3

2) Leukocytosis
>12,000/mm3 or
leukopenia
<3,000/mm3 and/or
left shift

2) Leukocytosis or
leukopenia (ranges
not specified)

3) Purulent tracheal
aspirate

3) Purulent tracheal
aspirate

3) Bronchoalveolar
lavage with at least
104 cfu/mL

4) A semiquantitative culture
of tracheal aspirate
samples that was
positive for
pathogenic bacteria

*All clinical
diagnoses of VAP
were evaluated and
agreed upon by two
of the authors

Sample size of the study population is an important factor when determining its clinical
relevance. Studies reviewed in this analysis had population sizes ranging from 100 to 235
patients (Table 2). The small sample sizes increase Type 2 error risk and are of concern in
clinical efficacy. The largest sample size was seen in Study 2, which was the single study that
showed statistical significance in VAP incidence in this review (Table 2). Sample sizes of this
range are not ideal due to the increased risk of Type 2 error. In other words, there is a higher
chance of accepting a false hypothesis, which does not contribute to clinical practice. A larger
sample size in the four studies analyzed would be an appropriate way to render research more
efficient and reliable concerning the effectiveness of probiotics in the prevention of VAP in
hospitalized patients.
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Table 2. An overview of each article reviewed in this literature, including study title, type, year published, number
of participants in the study, the composition of the probiotics used and their concentrations if stated, the primary
outcomes, and statistically significant findings.
Cfu = colony-forming units; VAP = ventilator-associated pneumonia

Conclusion
In reviewing the literature, data regarding probiotic use and VAP prevention vary
between meta-analyses. With the high incidence and mortality of VAP, as well as the increasing
rates of antibiotic resistance with the relative deficiency of new antibiotics, additional VAP
prevention options must be pursued. Probiotics are generally of no pathogenic concern and have
the potential to aid in immune responses to decrease infectious complications in mechanicallyventilated patients. However, as discussed, only one of the four studies reviewed was able to
show significantly reduced microbiologically-confirmed VAP with the supplementation of
probiotics. The three remaining studies were inconclusive in demonstrating efficacy of
probiotics.
There is significant variance among strains, concentrations, administration routes,
administration frequency, and VAP-prevention bundles used throughout these studies.
Additionally, there is variance between clinical diagnostic requirements of VAP. These
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differences make comparisons between studies and resultant clinical applications difficult to
determine. Recommendations for future research into VAP prevention would be a doubleblinded randomized controlled trial involving the use of B. subtilis and E. faecalis at the same
concentrations (Table 2) and diagnostic requirements (Table 1) as specified in Study 2.
Additional interest involves the use of LcS as specified in Study 1 though without the oral care
of chlorhexidine. In general, further research is needed to determine the efficacy of probiotics in
the clinical care and prevention of VAP.
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